What is the drug schedule classification of tadalafil (Cialis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tadalafil Drug Schedule Classification

Tadalafil is not a controlled substance and has no DEA schedule classification—it is a prescription-only medication available by prescription without controlled substance restrictions. 1

Regulatory Status

  • Tadalafil is FDA-approved for multiple indications including erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension, but carries no controlled substance scheduling 2, 3
  • The medication requires a prescription due to significant safety considerations, particularly the absolute contraindication with nitrate medications which can cause life-threatening hypotension 1, 4

Key Prescribing Restrictions

While tadalafil is not scheduled, prescribing requires critical safety verification:

  • Absolute contraindication: Patients taking nitrates in any form must not receive tadalafil due to risk of potentially fatal hypotension—a minimum 48-hour interval is required after the last tadalafil dose before nitrate administration 5, 1, 4
  • Cardiovascular screening required: Assess the patient's ability to perform moderate physical activity (walk 1 mile in 20 minutes or climb 2 flights of stairs) before prescribing, with cardiology referral for those unable to do so 1
  • Alpha-blocker caution: Combination with alpha-blocking agents like doxazosin requires hemodynamic stability and close blood pressure monitoring 4

Clinical Context

The lack of controlled substance status reflects tadalafil's mechanism as a phosphodiesterase type 5 inhibitor with no abuse potential, addiction risk, or psychoactive properties 6, 7. Its prescription-only status is based entirely on cardiovascular safety concerns rather than abuse liability 4.

References

Guideline

Tadalafil for Erectile Dysfunction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Tadalafil Use in Cardiovascular Disease.

Cardiology in review, 2025

Research

The cardiovascular safety of tadalafil.

Expert opinion on drug safety, 2008

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tadalafil (Cialis) for men with erectile dysfunction.

International journal of clinical practice, 2002

Research

Tadalafil in the treatment of erectile dysfunction.

Therapeutics and clinical risk management, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.